Information Services Group has reached an inflection point, shifting focus to GenAI advisory and leveraging its unique ProBenchmark platform. III's Q2 revenues grew 7%, and Adj EBITDA jumped 17%, ...

AstraZeneca and Daiichi Sankyo's Datroway improved survival outcomes over chemotherapy in advanced triple-negative breast cancer patients.

The benchmark indices of the NSE Nifty 50 and BSE Sensex on Tuesday exhibited gains for a fourth consecutive session, post which they closed flat.

Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech risks. Learn why VKTX stock is a strong buy.

Join us on the Wipro Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay in the know with the latest information about Wipro, including: Last traded ...

From financing the future of technology to advising on the IPO comeback, here's why these young finance leaders are the ones to watch in 2025.

The FTSE 100 index closed up 63.52 points, 0.7%, at 9,491.25, a new closing high, and just shy of a fresh intra-day best level of 9,494.64 hit earlier in the trading day. The FTSE 250 ended up 150.32 ...

The RBI MPC kept the repo rate unchanged at 5.50% and maintained the policy stance as ‘Neutral’. This marks the second consecutive pause following a cumulative 100 basis point (bps) rate cut earlier ...

The Wabtec deal is a big vote of confidence in US industry and diplomacy in Kazakhstan. However, any optimism must be tempered with realism.

The CBDT extended the Tax Audit deadline to Oct 31, 2025. GST Appellate Tribunal (GSTAT) was launched, and RBI mandated two-factor authentication for all digital ...

Investing.com -- UBS upgraded its rating on 3i Group (LON:III) to “buy” from “neutral,” raising its price target to £47 from £44.50. Shares of the private equity and venture capital company were up 3% ...

By stepping out as the first biopharma to win a three-year exemption from President Donald Trump’s earlier-announced plans for 100% tariffs, in return for agreeing to manufacture more of its drugs in ...